Activation of the cGAS–STING pathway by clofoctol through mitochondrial damage in triple-negative breast cancer Authors: Lusheng Wang, Lijie Zheng, Xiang Yong, Zhixian Ding, Jiting Sun, Yu Tang, Kemeng Tang, Yafen Li, Jie Chen, Shuaiyong Qi, Huaiyuan Hu, Heng Tang Published: 2025 ABSTRACT AbstractBackgroundTriple-negative breast cancer (TNBC) is an aggressive subtype of breast cancer that lacks effective targeted therapies. Drug repurposing offers a promising avenue for accelerating the discovery of novel treatments. Clofoctol, a synthetic antibacterial agent, has recently emerged as a potential anticancer candidate; however, its mechanisms of action in TNBC remain largely unclear.MethodsPotential targets of clofoctol in breast cancer were initially identified through network pharmacology and enrichment analysis. The predicted pathways were validated using a series of in vitro assays, including MTT and colony formation assays for cell proliferation, and flow cytometry for cell cycle distribution, apoptosis, mitochondrial membrane potential (MMP), and reactive oxygen species (ROS) levels. Western blotting was used to assess key regulatory proteins, while mitochondrial ultrastructure was examined via transmission electron microscopy. In vivo antitumor efficacy and systemic safety were evaluated using a 4T1 xenograft mouse model by monitoring tumor growth, body weight, and histopathological changes.ResultsClofoctol significantly inhibited TNBC cell proliferation, colony formation, and metastatic behaviors. Mechanistically, clofoctol induced G0/G1 phase arrest by downregulating CDK4 and Cyclin D1 and promoted apoptosis via mitochondrial dysfunction, characterized by MMP loss, elevated ROS generation, and cytochrome c release. Furthermore, clofoctol triggered mitochondrial DNA (mtDNA) leakage, which activated the cGAS–STING signaling pathway and led to phosphorylation of TBK1 and IRF3. In vivo, clofoctol markedly suppressed tumor growth in TNBC xenograft models without inducing notable systemic toxicity, while further validating that clofoctol activates antitumor immune responses.ConclusionClofoctol exerts potent anti-TNBC activity by integrating DNA damage response activation, mitochondrial apoptosis, and cGAS–STING pathway stimulation. Its dual cytotoxic and immunomodulatory effects, together with a favorable safety profile, underscore clofoctol’s promise as a repurposed therapeutic candidate for TNBC and warrant further evaluation in patient-derived and immunocompetent models.Supplementary InformationThe online version contains supplementary material available at 10.1186/s12967-025-07592-y.Keywords: Clofoctol, Triple-negative breast cancer, Mitochondrial apoptosis, cGAS–STING signaling pathway, Innate immune activation Background Triple-negative breast cancer (TNBC) is an aggressive subtype of breast cancer characterized by the absence of estrogen receptor (ER), progesterone receptor (PR), and HER2 expression, resulting in limited targeted therapeutic options and poor clinical outcomes [1–3]. TNBC exhibits high genomic instability and metabolic reprogramming, both of which contribute to intrinsic resistance and immune evasion [4]. Therefore, identifying therapeutic strategies that simultaneously induce tumor cell death and restore immune responsiveness remains an urgent need. The cyclic GMP–AMP synthase (cGAS)–stimulator of interferon genes (STING) pathway has emerged as a critical innate immune sensor of cytosolic double-stranded DNA (dsDNA) [5]. Upon activation, cGAS synthesizes cyclic GMP–AMP (cGAMP), which binds to STING and triggers TBK1/IRF3 phosphorylation, leading to type I interferon and pro-inflammatory cytokine production [6, 7]. In TNBC, the cGAS–STING pathway has been implicated in both anti-tumor immunity and therapeutic resistance, with recent studies showing that its activation can promote tumor immunogenicity and enhance responsiveness to immune checkpoint blockade [8, 9]. However, TNBC cells often exhibit impaired STING signaling, limiting endogenous immune activation and providing a rationale for pharmacologic restoration of this pathway. While activation of the cGAS–STING pathway can enhance anti-tumor immunity, excessive or sustained signaling may lead to systemic inflammation and autoimmune-like toxicities due to overproduction of type I interferons and proinflammatory cytokines [10]. Therefore, temporal and dosage control of STING activation will be critical to balance efficacy and safety in clinical translation. Mitochondrial dysfunction represents a key source of cytosolic DNA that can activate the cGAS–STING pathway [11]. In TNBC, metabolic stress and oxidative damage frequently disrupt mitochondrial integrity, leading to mitochondrial outer membrane permeabilization (MOMP) and release of mitochondrial DNA (mtDNA) into the cytoplasm [12, 13]. This mtDNA acts as a potent endogenous danger signal that engages cGAS and amplifies innate immune signaling. Thus, mitochondrial damage–induced cGAS–STING activation provides a mechanistic link between cellular stress and anti-tumor immune activation in TNBC. Clofoctol, a bacteriostatic antibiotic formerly approved for clinical use, has recently gained attention as a potential anticancer agent due to its ability to modulate endoplasmic reticulum stress, protein translation, and apoptotic pathways [14]. Prior studies identified clofoctol as an inhibitor of prostate cancer cell growth, linked to activation of stress responses and modulation of key regulatory pathways [15].Though its anti-cancer mechanisms remain incompletely defined, emerging evidence suggests clofoctol can influence cellular stress signaling and may impact mitochondrial function, positioning it as a candidate for triggering downstream innate immune activation [16]. In this study, we investigated the anti-TNBC effects of clofoctol and explored its underlying mechanisms. We demonstrate that clofoctol induces mitochondrial damage and mtDNA leakage, leading to activation of the cGAS–STING pathway and production of immune-stimulatory cytokines. These findings reveal a dual role of clofoctol in promoting tumor cell apoptosis and enhancing innate immune activation, highlighting its potential as a safe and repurposed therapeutic agent for TNBC. Materials and methods Cell culture and reagents The MDA-MB-231 and 4T1 cell lines were obtained from the Shanghai Cell Bank of the Chinese Academy of Sciences (Shanghai, China). Cells were cultured in RPMI-1640 medium (Gibco, USA) supplemented with 10% fetal bovine serum (FBS), 100 U/mL penicillin, and 100 µg/mL streptomycin at 37 °C in a humidified incubator with 5% CO₂. Clofoctol (purity ≥ 98%) was purchased from Shanghai Yuanye Bio-Technology Co., Ltd. (Shanghai, China) and dissolved in dimethyl sulfoxide (DMSO) to prepare stock solutions. Cell viability assay (MTT) Cell viability was assessed using the MTT assay. Cells were seeded in 96-well plates at a density of 8 × 10³ cells/well and allowed to adhere overnight. Following treatment with various concentrations of clofoctol for 48–72 h, 10 µL of MTT solution (Solarbio, China) was added to each well and incubated for 4 h. After discarding the supernatant, 200 µL of DMSO was added to dissolve the formazan crystals. Absorbance was measured at 490 nm using a microplate reader (Thermo Scientific, USA). Cell viability was calculated relative to untreated controls. Colony formation assay Approximately 500 cells were plated per well in six-well plates and allowed to attach overnight. After continued culture for 48 h, the medium was replaced with fresh medium containing varying concentrations of clofoctol. Colonies were cultured for 10–14 days, fixed with 4% paraformaldehyde for 15 min, and stained with 0.1% crystal violet, followed by PBS to remove excess stain. The stained colonies were then documented using a digital camera. Wound healing assay Cells were seeded in six-well plates and grown to near confluence. A uniform scratch was made across the cell monolayer using a sterile 200 µL pipette tip. Detached cells were removed with PBS, and cells were treated with clofoctol in serum-free medium. Images were captured at 0 h and after 24 h under an inverted microscope (Leica Microsystems CMS GmbH). Wound closure was quantified as the percentage of wound area reduction. Transwell migration and invasion assay For migration assays, 5 × 10⁴ cells suspended in serum-free medium containing different concentrations of clofoctol were seeded into the upper chamber of Transwell inserts (8 μm pore size, Corning). The lower chamber contained medium with 10% FBS. After 24 h, cells on the upper surface were removed, and migrated cells on the lower surface were fixed and stained with crystal violet. For invasion assays, the inserts were pre-coated with Matrigel (Corning). Cells were counted in five random fields under a microscope. Cell cycle analysis Cells treated with clofoctol for 24 h were harvested, washed with PBS, and fixed in 70% cold ethanol overnight at − 4 °C. After washing, cells were stained with propidium iodide (PI) solution containing RNase A for 30 min at room temperature in the dark. DNA content was analyzed by flow cytometry (Beckman Coulter), and cell cycle distribution was evaluated using ModFit software. Apoptosis analysis by flow cytometry Cells were treated with clofoctol for 24 h, collected, washed with PBS, and resuspended in binding buffer. Annexin V-FITC/PI dual staining (Beyotime Biotechnology) was performed according to the manufacturer’s protocol. Samples were analyzed on a flow cytometer (Beckman Coulter). Early and late apoptotic cells were quantified as the sum of Annexin V-positive populations. Mitochondrial membrane potential assessment JC-1 dye (Beyotime Biotechnology) was used to measure MMP. Cells were incubated with JC-1 staining solution at 37 °C for 20 min, washed with buffer, and analyzed by flow cytometry. The ratio of red (aggregates) to green (monomers) fluorescence indicated MMP changes. Reactive oxygen species (ROS) measurement Intracellular ROS levels were evaluated using DCFH-DA probe (Beyotime Biotechnology). Cells treated with clofoctol were incubated with 10 µM DCFH-DA at 37 °C for 20 min, washed, and analyzed for fluorescence intensity using flow cytometry. Mean fluorescence intensity reflected ROS accumulation. Detection of MtDNA release by qPCR After 24 h of clofoctol treatment, cells were collected, and 5 × 10⁶ cells from both the control and treatment groups were divided into two equal portions. (a) Total DNA was extracted from one portion using a DNA extraction kit (Vazyme) according to the manufacturer’s instructions, to serve as a standardized control for mtDNA. (b) The second portion was resuspended in 500 µl of buffer containing 150 mM NaCl, 50 mM HEPES (pH 7.4), and 25 µg/ml digitonin. The samples were incubated for 10 min and then centrifuged at 980 × g for 3 min at 4 °C, and this step was repeated three times to pellet intact cells. The cytoplasmic supernatant was subsequently centrifuged at 17,000 × g for 20 min to remove residual cell debris. Quantitative PCR was performed on total cellular DNA and cytoplasmic DNA using nuclear and mitochondrial DNA primers. The CT value of total cellular DNA abundance was used as the standard control for mtDNA derived from the cytoplasmic fraction. Transmission electron microscopy (TEM) Cells were treated with clofoctol for 24 h, collected, washed with PBS. Cells were fixed in 2.5% glutaraldehyde overnight at 4 °C, post-fixed with 1% osmium tetroxide, dehydrated in graded ethanol, and embedded in epoxy resin. Ultrathin sections were stained with uranyl acetate and lead citrate. Mitochondrial morphology was examined under a transmission electron microscope (Hitachi). Western blot analysis TNBC cells were treated with the indicated concentrations of clofoctol for 24 h. After treatment, cells were rinsed twice with cold PBS and lysed in RIPA buffer (Beyotime, China) containing protease and phosphatase inhibitors (Thermo Fisher Scientific, USA). Lysates were incubated on ice for 30 min and centrifuged at 12,000 × g for 15 min at 4 °C. Supernatants were collected, and protein concentrations were determined using a BCA assay kit (Beijing Solarbio Science & Technology Co.,Ltd, China). Equal amounts of protein were separated by SDS-PAGE and transferred to PVDF membranes (Millipore, USA). Membranes were blocked in 5% non-fat milk in TBST for 1 h at room temperature and incubated overnight at 4 °C with primary antibodies against H2A.X(#AB11174, abcam), CDK4(#AB108357, abcam), Cyclin D1(#AB134175, abcam), Bcl-2(#26593, Proteintech), Bax(#60267, Proteintech), Caspase-3(#9662, Cell Signaling), cleaved Caspase-3(#9664, Cell Signaling), Cytochrome C(#66264, Proteintech), cGAS(#26416, Proteintech), STING(#66680, Proteintech), phospho-STING(#50907, Cell Signaling), phospho-TBK1(#82382, Proteintech), phospho-IRF3(#29528, Proteintech) and β-actin(#66009, Proteintech). After washing, membranes were incubated with secondary antibodies for 2 h at room temperature.Signals were detected using ECL reagents (Bio-Rad, USA) and visualized with a fully automatic chemiluminescence image analysis system (Shanghai Tanon). Band intensities were quantified using ImageJ software. Animal experiments Female BALB/c mice (4–6weeks old, 16–20 g) were purchased from Jiangsu Collaborative Pharmaceutical Bioengineering Co., Ltd and maintained under specific pathogen-free conditions with free access to food and water. All animal experiments were conducted in accordance with the ethical guidelines of the ethics committee of Wanbei Coal and ElectricityGroup General Hospital, following internationally recognized standards for laboratory animal welfare. 4T1 murine breast cancer cells were harvested in the logarithmic growth phase, washed with PBS, and resuspended in PBS. A suspension containing 2 × 10⁶ cells in 100µL PBS was injected subcutaneously into the right flank of each mouse. Tumor volume and body weight were monitored every two days throughout the experimental period. Once tumors reached an average volume of approximately 50–100 mm³, mice were randomly assigned to one of three groups (n = 8 per group): Control, Low-dose (20 mg/kg clofoctol), and High-dose (40 mg/kg clofoctol). Clofoctol was dissolved in 0.5% carboxymethylcellulose sodium and administered via intraperitoneal injection once every two days for 14 days. Control mice received an equal volume of the vehicle alone. Tumor dimensions were measured with digital calipers, and tumor volume was calculated using the formula: Tumor volume (mm³)=(Length×Width2)/2. At the end of the treatment period, mice were euthanized, and tumors were excised, weighed, and collected for further analyses. Flow cytometry analysis of the tumor microenvironment After tumor collection, tissues were minced into 1–3 mm³ fragments and digested at 37 °C for 30 min in RPMI-1640 containing collagenase IV (1 mg/mL), hyaluronidase (0.2 mg/mL), and DNase I (0.2 mg/mL). The digests were filtered through a 70 μm strainer, centrifuged at 350 × g for 8 min, treated with RBC lysis buffer for 3 min on ice, and resuspended in PBS with 1% FBS for analysis. Spleens were mechanically dissociated, passed through a 70 μm strainer, and treated with RBC lysis buffer (15 min on ice). After washing, single-cell suspensions were prepared for flow cytometry. For antibody staining, cells (2 × 10⁶ cells/mL) were first incubated with an Fc receptor blocker for 10 min to minimize non-specific binding. They were then stained in the dark at room temperature for 20 min with the following fluorochrome-conjugated anti-mouse antibodies: CD45-FITC (MultiSciences), CD3-APC (MultiSciences), CD4-PE-Cy7 (MultiSciences), and CD8-APC-Cy7 (MultiSciences). Following a final wash, cells were analyzed using a flow cytometer, and the acquired data were processed with FlowJo software (version 10.0). Statistical analysis All experiments were performed with a minimum of three independent biological replicates. Data are presented as mean ± SD. Statistical analyses were carried out using Student’s t-test for comparisons between two groups or one-way ANOVA for multiple group comparisons, followed by post-hoc tests where appropriate. A p-value of less than 0.05 was considered statistically significant. All statistical analyses were performed using GraphPad Prism, and data normality was assessed prior to analysis. Results Clofoctol targets are enriched in DNA damage–related pathways To delineate the molecular mechanisms through which clofoctol might exert its anti-tumor activity, we first examined its chemical structure (Fig. 1A) and subsequently performed a network pharmacology analysis. Potential targets of clofoctol were predicted using the SwissTargetPrediction and PharmMapper databases, while breast cancer–associated genes were retrieved from GeneCards. By intersecting these datasets, we identified 26 overlapping genes (Fig. 1B). The resulting drug–disease–target interaction network (Fig. 1C) revealed that these common targets were highly connected with pathways governing cell cycle progression, apoptosis regulation, and genomic stability. GO enrichment analysis further demonstrated significant enrichment in histone kinase activity, particularly phosphorylation of histone H2A.X and H3, which are directly involved in DNA damage response (DDR) and chromatin remodeling (Fig. 1D). Considering the critical role of DDR in maintaining genomic stability and regulating cancer cell fate, these bioinformatics results suggested that clofoctol might impair breast cancer cell viability by promoting DNA damage and subsequent activation of checkpoint signaling cascades. Importantly, this computational prediction provided a theoretical foundation for our subsequent in vitro and in vivo validation experiments. Network pharmacology analysis of clofoctol against breast cancer. (A) Chemical structure of clofoctol. (B) Venn diagram of overlapping targets between breast cancer and clofoctol. (C) Drug–disease–target interaction network. (D) GO enrichment analysis of shared targets Clofoctol suppresses proliferation of TNBC cells via induction of G0/G1 arrest To experimentally validate the above predictions, we next examined the effects of clofoctol on TNBC cell proliferation. MTT assays demonstrated a robust, time- and dose-dependent reduction in cell viability in both MDA-MB-231 and 4T1 cells. After 48 h of treatment, the IC₅₀ values were 22.70 ± 2.75 µM and 18.03 ± 0.33 µM, respectively, underscoring the potent cytotoxic activity of clofoctol (Fig. 2A). Long-term proliferation, evaluated by colony formation assays, was markedly impaired, with a pronounced decline in colony number and size in a concentration-dependent manner (Fig. 2B-C). Mechanistic analysis of the cell cycle distribution revealed a significant accumulation of cells in the G0/G1 phase following clofoctol treatment (Fig. 2D-E). This indicated that clofoctol enforced a checkpoint blockade at the G1–S transition. Consistently, Western blotting confirmed dose-dependent downregulation of Cyclin D1 and CDK4, two key drivers of G1 progression, along with increased phosphorylation of H2A.X (γH2A.X), a canonical marker of DNA double-strand breaks (Fig. 2F). Collectively, these findings indicated that clofoctol exerted its anti-proliferative activity by inducing DNA damage and triggering G0/G1 arrest, thereby halting uncontrolled TNBC cell proliferation. Clofoctol suppresses proliferation and induces G0/G1 cell cycle arrest in TNBC cells. (A) MTT assay showing dose- and time-dependent inhibition of cell viability in MDA-MB-231 and 4T1 cells after 24 h, 48 h and 72 h of clofoctol treatment. (B) Colony formation assay demonstrating reduced clonogenic survival following clofoctol exposure. (C) Quantification of colony numbers from (B). (D) Flow cytometry analysis indicating G0/G1 cell cycle arrest in response to clofoctol treatment. (E) Quantification of cell cycle phase proportions in (D). (F) Western blot analysis of CDK4, Cyclin D1, and H2A.X expression levels after 24 h of clofoctol treatment. Data are presented as mean ± SD from three independent experiments. Statistical significance was determined using one-way ANOVA for multiple group comparisons. *p < 0.05, **p < 0.01, ***p < 0.001 Clofoctol inhibits tumor growth in vivo Finally, the anti-tumor efficacy of clofoctol was validated in vivo using a 4T1 xenograft nude mouse model. Tumor-bearing mice were treated with clofoctol at 20 or 40 mg/kg, while control animals received vehicle only. Clofoctol significantly suppressed tumor growth in a dose-dependent manner, as reflected by both reduced tumor volumes over time and smaller tumor weights at the experimental endpoint (Fig. 3A-B, D). Importantly, body weight monitoring showed no significant differences between treated and control groups throughout the study period (Fig. 3C), suggesting that clofoctol was well tolerated at the tested doses. Moreover, histological evaluation of major organs (heart, liver, spleen, lung, kidney) by H&E staining revealed no evidence of structural damage, inflammation, or other pathological alterations (Fig. 3E). Collectively, these findings provided compelling preclinical evidence that clofoctol effectively suppressed TNBC tumor growth while exhibiting minimal systemic toxicity, underscoring its translational potential as a therapeutic candidate for breast cancer. Clofoctol suppresses tumor growth in a xenograft model. (A) Representative images of tumors excised from nude mice treated with vehicle, Clofoctol (20 mg/kg), or Clofoctol (40 mg/kg). (B) Tumor volume curves over 14 days showing dose-dependent inhibition of tumor growth by Clofoctol. (C) Body weight monitoring over the treatment period revealed no significant weight loss in Clofoctol-treated groups. (D) Final tumor weights at day 14 demonstrate significant reductions following Clofoctol treatment. (E) H&E staining of major organs (heart, liver, spleen, lung, kidney) revealed no histopathological abnormalities, indicating minimal systemic toxicity. Data are presented as mean ± SD from eight mice per group (n = 8). Statistical significance was assessed using one-way ANOVA for multiple group comparisons. *p < 0.05, **p < 0.01, ***p < 0.001 Clofoctol attenuates the migratory and invasive potential of TNBC cells Given the aggressive clinical behavior of TNBC, characterized by early metastasis and poor prognosis, we investigated whether clofoctol could suppress metastatic traits. Wound healing assays showed that clofoctol significantly inhibited horizontal migration of both MDA-MB-231 and 4T1 cells after 24 h, with inhibitory effects increasing in a dose-dependent fashion (Fig. 4A-B). These observations were supported by Transwell migration assays, which demonstrated a striking reduction in the number of cells traversing the membrane following clofoctol treatment (Fig. 4C-D). Furthermore, Transwell invasion assays using Matrigel-coated membranes revealed that clofoctol profoundly suppressed invasive ability in both cell lines in a dose-dependent manner (Fig. 4E-F). The combined data clearly demonstrate that clofoctol not only impaired tumor cell proliferation but also significantly limited their capacity for migration and invasion, thereby attenuating metastatic potential in vitro. These anti-metastatic properties suggested a broader therapeutic relevance of clofoctol beyond simple growth inhibition. Clofoctol inhibits migration and invasion of TNBC cells. (A) Representative images of wound healing assays showing reduced migratory ability of MDA-MB-231 and 4T1 cells after 24 h of clofoctol treatment. (B) Quantification of wound closure percentage relative to the initial gap width. (C)Transwell migration assays demonstrating dose-dependent inhibition of cell migration by clofoctol. (D) Quantification of migrated cells in (C). (E) Transwell invasion assays showing dose-dependent suppression of invasive capacity. (F) Quantification of migrated and invaded cells in (E). Data are presented as mean ± SD from at least three independent experiments. Statistical significance was determined by unpaired two-tailed Student’s t-test for two-group comparisons and one-way ANOVA for comparisons among multiple groups. *p < 0.05, **p < 0.01, ***p < 0.001 Clofoctol promotes apoptosis through activation of the intrinsic pathway To further explore the cytotoxic mechanisms of clofoctol, we assessed its effects on apoptosis. Flow cytometric analysis using Annexin V-FITC/PI staining demonstrated a clear dose-dependent increase in apoptotic cell populations in both MDA-MB-231 and 4T1 cells after 24 h of treatment (Fig. 5A-B). At the molecular level, Western blot analysis revealed upregulation of the pro-apoptotic protein Bax, downregulation of the anti-apoptotic protein Bcl-2, and enhanced cleavage of pro-caspase-3 into its active form (Fig. 5C). This molecular signature was consistent with activation of the intrinsic apoptotic pathway, where the balance between pro- and anti-apoptotic factors dictated cell fate. The concomitant activation of caspase-3, a key executioner caspase, further underscored the robust induction of apoptosis. Together, these results demonstrated that clofoctol triggered apoptosis in TNBC cells primarily through mitochondrial-dependent intrinsic mechanisms. Clofoctol induces apoptosis in TNBC cells. (A) Flow cytometry analysis of Annexin V-FITC/PI-stained MDA-MB-231 and 4T1 cells after 24 h of clofoctol treatment, showing a dose-dependent increase in apoptotic cell populations. (B) Quantification of apoptotic cells in (A). (B) Western blot analysis of apoptosis-related proteins in MDA-MB-231 and 4T1 cells following 24 h of treatment. Data are presented as mean ± SD from three independent experiments. Statistical significance was determined using one-way ANOVA for multiple group comparisons. *p < 0.05, **p < 0.01, ***p < 0.001 Clofoctol disrupts mitochondrial function and enhances ROS production Mitochondria served as central regulators of intrinsic apoptosis; therefore, we next evaluated mitochondrial function following clofoctol exposure. JC-1 staining revealed a pronounced loss of MMP in both TNBC cell lines, reflected by a shift from red to green fluorescence, which occurred in a dose-dependent manner (Fig. 6A-B). In parallel, intracellular ROS levels measured by DCFH-DA staining were significantly elevated, indicating that clofoctol induced a state of oxidative stress (Fig. 6C-D). Consistent with these findings, Western blot analysis confirmed a dose-dependent increase in cytochrome c release into the cytosolic fraction, signifying MOMP (Fig. 6E). Together, these results demonstrated that clofoctol compromised mitochondrial integrity, elevated ROS production, and facilitated cytochrome c release, thereby amplifying apoptotic signaling. Such mitochondrial dysfunction is not only a trigger for apoptosis but also a key factor linking metabolic stress to immune signaling pathways. Clofoctol induces mitochondrial dysfunction and ROS accumulation in TNBC cells. (A) JC-1 staining and flow cytometry revealed a dose-dependent loss of MMP in MDA-MB-231 and 4T1 cells following 24 h of Clofoctol treatment. (B) Quantification of MMP in (A). (C) Intracellular ROS levels, measured by DCFH-DA staining, increased significantly in a dose-dependent manner after 24 h treatment. (D) Quantification of ROS levels in (C). (E) Western blot analysis showed enhanced cytosolic release of cytochrome c in response to Clofoctol. Data are presented as mean ± SD from three independent experiments. Statistical significance was determined using one-way ANOVA for multiple group comparisons. *p < 0.05, **p < 0.01, ***p < 0.001 Clofoctol induces MtDNA release and activates the cGAS–STING pathway To determine whether clofoctol-induced mitochondrial damage leads to innate immune activation, we examined cytosolic mtDNA levels and cGAS–STING signaling activity. qPCR analysis demonstrated significant enrichment of mtDNA genes (ND1, ND4, CO1, Dloop1, Dloop2, cytb) in the cytosolic fractions of both cell lines after 24 h of clofoctol treatment (Fig. 7A). TEM analysis further revealed profound mitochondrial structural disruption, including swelling, cristae fragmentation, and reduced matrix density (Fig. 7B). In line with these morphological changes, Western blotting showed dose-dependent phosphorylation of STING, TBK1, and IRF3 (Fig. 7C). These results established a mechanistic link between clofoctol-induced mitochondrial injury, mtDNA release, and subsequent activation of the cGAS–STING pathway, which has been increasingly recognized as a crucial mediator of tumor cell-intrinsic immune responses. Clofoctol activates the cGAS–STING signaling pathway in breast cancer cells. (A) Quantification of cytosolic mtDNA in MDA-MB-231 and 4T1 cells after 24 h of clofoctol treatment (22 µM), measured by qPCR for ND1, ND4, CO1, Dloop1, Dloop2, and cytb genes. (B) TEM images showing mitochondrial swelling and cristae disruption in clofoctol-treated cells. Scale bars: 2 μm (low magnification), 500 nm (high magnification). (C) Western blot analysis of cGAS–STING pathway proteins (cGAS, STING, p-STING, p-TBK1, and p-IRF3) in cells treated with increasing concentrations of clofoctol for 24 h. Data are presented as mean ± SD from three independent experiments. Statistical significance was determined using one-way ANOVA for multiple group comparisons. *p < 0.05, **p < 0.01, ***p < 0.001 Clofoctol enhances anti-tumor immune activation in BALB/c mice To further evaluate clofoctol impact on the immune microenvironment, a 4T1 syngeneic BALB/c mouse model was established (Fig. 8A). Clofoctol administration (20 mg/kg or 40 mg/kg) markedly reduced tumor size compared with the control group. Representative tumor images (Fig. 8B) and final tumor weights (Fig. 8C) demonstrated a significant and dose-dependent inhibition of tumor growth. Consistently, tumor volume monitoring revealed a pronounced reduction in tumor progression in clofoctol-treated mice (Fig. 8D), while body weight remained stable across all groups, indicating good tolerability (Fig. 8E). Flow cytometric analysis of immune cell populations revealed that clofoctol modulated systemic and intratumoral immunity. In the spleen, the proportion of CD3⁺CD8⁺ T cells showed a modest upward trend with increasing clofoctol dose (Fig. 8F–G). Notably, a more substantial increase in CD3⁺CD8⁺ cytotoxic T cells was observed within tumor tissues in a dose-dependent manner (Fig. 8H–I), indicating enhanced local anti-tumor immune activity. Correspondingly, key effector cytokines, including IFN-γ and IL-2, were significantly elevated in tumor tissues following clofoctol treatment (Fig. 8J–K), further supporting augmented cytotoxic T-cell activation. Histological staining corroborated these findings. Ki-67 levels were decreased in clofoctol-treated tumors, reflecting reduced proliferative activity, whereas TUNEL staining demonstrated progressively increased apoptosis at higher doses (Fig. 8L). Together, these data indicate that clofoctol not only suppresses tumor growth but also improves cytotoxic T-cell–mediated anti-tumor immunity in vivo. Clofoctol enhances anti-tumor immune responses in BALB/c mice bearing 4T1 tumors. (A) Schematic of the in vivo experimental design. (B) Representative images of excised tumors at the end of treatment. (C) Quantification of final tumor weights. (D) Tumor volume growth curves during treatment. (E) Body weight monitoring showing no significant toxicity. (F) Representative flow cytometry plots of CD3⁺CD8⁺ T cells in spleens from each treatment group. (G) Quantification of splenic CD8⁺ T-cell percentages. (H) Representative flow cytometry plots of CD3⁺CD8⁺ T cells within tumor tissues. (I) Quantification of intratumoral CD8⁺ T-cell percentages. (J–K) Levels of IFN-γ and IL-2 in tumor lysates measured after treatment. (L) Immunohistochemistry of Ki-67 and TUNEL staining showing reduced proliferation and increased apoptosis with increasing clofoctol doses. Scale bar: 100 μm. Data are presented as mean ± SD from eight mice per group (n = 8). Statistical significance was assessed using one-way ANOVA for multiple group comparisons. *p < 0.05, **p < 0.01, ***p < 0.001 Discussion TNBC remains one of the most challenging breast cancer subtypes to treat due to its intrinsic heterogeneity, high metastatic propensity, and lack of targeted therapies [17, 18]. In this context, drug repurposing offers a pragmatic route to accelerate therapeutic development by leveraging known safety profiles while addressing complex oncogenic dependencies [19–21]. Here, we demonstrate that clofoctol exhibits potent anti-TNBC activity via a multifaceted mechanism that integrates disruption of cell cycle progression, mitochondrial integrity, and engagement of innate immune signaling, features that may be particularly advantageous in treatment-refractory and highly plastic tumors. A central finding of our study is that clofoctol induces DNA damage and activates the associated checkpoint responses, evidenced by increased γH2A.X and G0/G1 arrest. Exploiting DNA repair vulnerabilities, for example through synthetic lethality with PARP inhibition, has emerged as an effective strategy in TNBC, particularly in tumors with homologous recombination deficiencies [22–24]. Clofoctol’s induction of genomic stress likely sensitizes cancer cells to proliferative blockade and apoptotic priming, aligning with these therapeutic paradigms. Beyond proliferation, clofoctol significantly impaired migratory and invasive phenotypes, thereby potentially suppressing both local growth and metastatic dissemination—two interlinked contributors to poor outcomes in TNBC [25, 26]. This dual action underscores its value not merely as a cytostatic agent but as one that can modulate the invasive behavior characteristic of aggressive breast cancers. Mechanistically, mitochondria emerge as a hub for clofoctol’s pro-apoptotic effect. We observed loss of MMP, elevated ROS, and release of cytochrome c, collectively reflecting mitochondrial dysfunction and initiation of the intrinsic apoptotic cascade [27–29]. Such perturbations not only commit cells to apoptosis but also result in leakage of mtDNA, which serves as a DAMP to activate innate immune sensing [30–32]. Consistent with this, clofoctol-induced mtDNA release activated the cGAS–STING pathway, aligning with known mechanisms whereby cytosolic DNA engages cGAS to stimulate downstream TBK1/IRF3 signaling and type I interferon responses (Fig. 9). Schematic illustration of the proposed mechanism by which clofoctol exerts anti-tumor effects in TNBC Activation of cGAS–STING in breast cancer is context-dependent and has been implicated in shaping tumor immunogenicity, with evidence showing its expression correlates with genomic instability and immune infiltration, especially in TNBC [6, 33]. While acute engagement of this pathway can promote anti-tumor immunity, chronic or dysregulated activation may contribute to immune tolerance or evasion, underscoring the need for precise temporal modulation in therapeutic applications [34–36]. Notably, clofoctol has been reported to modulate the unfolded protein response (UPR) and disrupt protein homeostasis, which are closely linked to cellular stress signaling [15]. ER stress and UPR activation can crosstalk with mitochondrial function, promoting mitochondrial ROS production and outer membrane permeabilization, both of which are known triggers of cytosolic DNA release and subsequent cGAS–STING activation. Thus, the observed activation of the cGAS–STING pathway in our study may result from a combination of direct mitochondrial perturbation and ER stress–mediated mitochondrial signaling. This integrated stress response induced by clofoctol likely contributes to acute cGAS–STING activation, favoring immunogenic cell death and enhancing anti-tumor immunity, thereby providing a rationale for its potential combination with immune checkpoint blockade or other immunomodulatory therapies. Despite the comprehensive data generated in this study, several limitations remain. Although we incorporated both immunodeficient xenograft models and an immunocompetent BALB/c 4T1 model to evaluate the antitumor and immune-stimulatory effects of clofoctol, these systems still cannot fully recapitulate the complexity of human tumor–immune interactions, and the extent to which mtDNA leakage and cGAS–STING signaling shape the immune microenvironment in patients requires further investigation. The temporal dynamics of cGAS–STING activation were assessed at selected time points, leaving the duration and fluctuation patterns of pathway activation unresolved—an important consideration given that transient activation may enhance antitumor immunity, whereas sustained signaling could potentially promote immune adaptation or tolerance. Moreover, the pharmacokinetic and pharmacodynamic profiles of clofoctol in the oncological context remain to be systematically evaluated, which will be essential to optimize clinical dosing and treatment regimens. Additional studies are also needed to elucidate whether the activation of the cGAS–STING pathway by clofoctol is transient or sustained, as the temporal dynamics of this signaling axis may critically determine whether the immune response is cytotoxic or tolerogenic. In conclusion, this study provides a comprehensive preclinical framework supporting clofoctol as a repurposed therapeutic for TNBC. Further validation in immune-competent models and clinical pharmacology studies will be essential to advance its translational potential toward precision oncology applications. Supplementary Information Below is the link to the electronic supplementary material. Supplementary Material 1 Acknowledgements Not applicable. Author Contributions Funding acquisition and Writing, LSW, LJZ. Investigation, LSW, LJZ, XY and ZXD. Design of the experiment, JTS, YT and KMT. Data curation, YFL, JC and SYQ. Writing review & editing, HT, HYH. All authors have read and approved the final manuscript. Funding This work is supported by the Science and Technology Research Project of Anhui Province (SZWJ2024a050) and (SZZCXM202539). Data availability The data and supporting materials regarding the findings of this study are accessible in the main document as well as in additional information. Declarations Ethics approval and consent to participate The study adhered to the principles outlined in The Declaration of Helsinki. All of mouse experi-ments have been approved by Ethics Committee of Wanbei Coal and Electricity Group General Hospital (No. WBZY-LLWYH-2024-037) and have been performed in accordance with relevant institutions and national guidelines and regulations. Consent to participate Not applicable. Consent for publication All authors have read the manuscript and provided their consent for the submission. Competing interests The authors declare no competing interests. Footnotes Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. Lusheng Wang and Lijie Zheng contributed equally to this work. Contributor Information Huaiyuan Hu, Email: Huaiyuan.hu@anweikang.cn. Heng Tang, Email: tangheng@mail.ustc.edu.cn. References Associated Data Supplementary Materials Supplementary Material 1 Data Availability Statement The data and supporting materials regarding the findings of this study are accessible in the main document as well as in additional information.